For: | Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 [PMID: 36338892 DOI: 10.3748/wjg.v28.i39.5750] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v28/i39/5750.htm |
Number | Citing Articles |
1 |
Jiayang Yu, Yufei Zhang, Chun-Guang Wang, Wei Yang, Fen Chen. Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysis. Dermatologica Sinica 2025; 43(2): 107 doi: 10.4103/ds.DS-D-24-00059
|
2 |
Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim. Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer. The Korean Journal of Internal Medicine 2025; 40(1): 49 doi: 10.3904/kjim.2024.135
|
3 |
Masaya Iwamuro, Sakiko Hiraoka, Motoyuki Otsuka. A case of immune checkpoint inhibitor-associated colitis treated with infliximab. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 2024; 136(2): 69 doi: 10.4044/joma.136.69
|
4 |
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1122430
|
5 |
Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Mark A Socinski, Guru Sonpavde, Javier Puente, Laurent Essioux, Corey Carter, Jose Vicente Cardona, Rajat Mohindra, Jarushka Naidoo. Correlation of safety and efficacy of atezolizumab therapy across indications. Journal for ImmunoTherapy of Cancer 2024; 12(11): e010158 doi: 10.1136/jitc-2024-010158
|
6 |
Anas Zaher, Maria Julia Moura Nascimento Santos, Hassan Elsaygh, Stephen J. Peterson, Carolina Colli Cruz, Anusha Shirwaikar Thomas, Yinghong Wang. Management of refractory checkpoint inhibitor-induced colitis. Expert Opinion on Drug Safety 2025; : 1 doi: 10.1080/14740338.2025.2496431
|